Universal Vaccine Advancement through AI and Recombinant Technology
Video credit: Sino Biological
Show Notes:
In this podcast, News talks with Dr. Amy Sheng, a technical account manager at Sino Biological, and Dr. Lurong Pan, the founder, and CEO of Ainnocence, an AI-powered, next-generation biotech startup.
Topics discussed include how AI can be used in combination with high throughput production and screening of proteins to expedite the development process for candidate universal vaccines – an ideal method for preventing and controlling future pandemics but also one of the major research challenges in biotechnology today.
Universal Vaccines are an ideal way to prevent future pandemics and are in great demand to control the current ever-evolving pathogen causing a lasting pandemic. Both preventive and therapeutic vaccines are very hard to develop using traditional methods, and universal vaccines are even harder. However, we can leverage AI and integrate protein science in universal protein vaccine design to expedite the process, possibly from years to months.
Our AI can generate antigen sequences by learning all past infectious pathogen proteomes and compute up to 10^10-25 times antigen-antibody interactions within several days to identify the common immunogenicity. The common immunogen can be computed based on respective cross-binding capability with known human plasma antibodies for B-cell immunogenicity assessment; T-cell immunogenicity will be accessed by computing the numerated computer-generated antigens against all MHC binding. By high-throughput production, screening and validation, ideal candidates for universal vaccine study can be realized and selected out.
Preview Clip
About Dr. Amy Sheng:
Amy Sheng, Ph.D., is a technical account manager in Sino Biological. Amy joined Sino Biological in 2021 supporting CRO services and project management in Eastern US region.
Prior to joining Sino Biological, she worked in Caprico Biotechnologies as production manager in charge of antibody development and production for flow cytometry. She has a PhD in Molecular and Cell Biology from Georgia Institute of Technology, and is ASCP-certified molecular biologist and ASQ-certified CSSGB.
Sino Biological is an internationally leading reagent manufacturer and service provider. All of Sino’s products are independently developed and produced. These products include recombinant proteins, antibodies and cDNA clones.
About Dr. Lurong Pan:
Dr. Lurong Pan is the founder and CEO of Ainnocence, an AI-powered, next-generation biotech startup. She has extensive drug design and precision medicine research experience using structural biology, computational chemistry, and artificial intelligence technologies.
She was previously a senior investigator at Global Health Drug Discovery Institute and a research scientist in structural biology and computational biology at University of Alabama at Birmingham. Dr. Pan received her B.S. in Applied Chemistry from Nanjing University, M.S. in Computer Science from Georgia Tech, and Ph.D. in Chemistry from University of Alabama at Birmingham. She is also an IBM-certified big data architect.
Website: www.ainnocence.com
LinkedIn: https://www.linkedin.com/company/ainnocence/
Twitter: Ainnocence (@Ainnocence_Inc) / Twitter